Article

TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.

Infanta Elena Hospital, Huelva, Spain.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology (impact factor: 0.41). 05/2008; 30(2):105-12. pp.105-12
Source: PubMed

ABSTRACT To identify markers of response to therapy in neuroblastic tumors.
A total of 58 patients with neuroblastic tumor (38 neuroblastomas, 13 ganglioneuroblastomas and 7 ganglioneuromas) were included in the study. TP53, BCL-2, p21Waf1/Cip1 and metallothionein were included as a biologic approach to tumor differentiation, response to therapy and prognosis.
Patients who died of disease had the following immunophenotype: BCL-2 (9 of 10), nuclear TP53 (7 of 10) and metallothionein (7 of 10). TP-53 expression was related to clinical stage (p = 0.062) and disease outcome (p = 0.0218). All patients in whom treatment failed expressed metallothionein (3 of 3).
TP53, BCL-2, p21Waf1/Cip1 and metallothionein had limited value reflecting tumor maturation (differentiation) or predicting response to therapy. Only nuclear TP53 accumulation may be relevant in patient's prognosis.

0 0
 · 
0 Bookmarks
 · 
16 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

13 ganglioneuroblastomas
 
38 neuroblastomas
 
58 patients
 
7 ganglioneuromas
 
biologic approach
 
clinical stage
 
disease outcome
 
markers
 
neuroblastic tumor
 
neuroblastic tumors
 
nuclear TP53
 
nuclear TP53 accumulation
 
patients
 
TP-53 expression
 
tumor differentiation
 
tumor maturation